Loading clinical trials...

Blended Resources for Integrated Diabetes Guidance and Empowerment | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Blended Resources for Integrated Diabetes Guidance and Empowerment

Effectiveness and Implementation of an AI-Driven Blended Care Model for Type 2 Diabetes Management in Primary Care: A Single-Blind, Cluster Randomized Controlled Trial in Zhangjiagang, China

NCT07373379•Peking University

View on ClinicalTrials.gov

Summary

The goal of this cluster randomized clinical trial is to learn if an AI-enabled blended care model (the BRIDGE program) works to treat type 2 diabetes in adults. It will also learn about the cost-effectiveness and implementation feasibility of this model in primary care settings. The main questions it aims to answer are: Does the AI-driven intervention lower HbA1c levels (blood sugar) compared to standard care? Does this model improve participants' quality of life, self-management behaviors, and digital literacy? Researchers will compare the "Diet-Medicine Companion" (Shi Yi Ban Lv) mini-program combined with family doctor support to standard community care to see if the blended care model works to manage diabetes. Participants will: Use the "Diet-Medicine Companion" mini-program to upload diet photos daily and receive AI feedback for 6 months Receive periodic guidance and phone reminders from case administrators (family doctors) Complete questionnaires and blood tests (HbA1c) at baseline, 3 months, and 6 months

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 18 to 70 years (inclusive).
•Glycosylated hemoglobin (HbA1c) level ≥ 6.5%.
•Resided in the local area for at least 6 months.
•Capable of using a smartphone to take photos and use the WeChat mini-program.
•Willing and able to provide informed consent.

Exclusion Criteria

•Diagnosed with Type 1 diabetes, gestational diabetes, or secondary diabetes.
•Presence of severe diabetic complications.
•Received radiotherapy or chemotherapy within the past 6 months.
•Diagnosed with severe intellectual disabilities, Alzheimer's disease, or other serious psychiatric disorders.
•Current participation in other research projects that may affect the results of this study.
•Presence of other severe disabilities or medical conditions deemed unsuitable for participation by the investigators.

Key Dates

Start Date

March 1, 2026

Primary Completion Date

March 1, 2026

Completion Date

October 30, 2026

Last Updated

February 23, 2026

Enrollment

1,200

ESTIMATED participants

Conditions

Type 2 Diabetes Mellitus

Interventions

AI-driven Dietary Management and Human-in-the-loop Support

DEVICE

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049

Type 2 Diabetes Mellitus (T2DM)Diabetes Distress

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Blended Resources for Integrated Diabetes Guidance and Empowerment

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Achieving Routine Intervention and Screening for Emotional Health

Human Immunodeficiency Virus (HIV) Food Insecurities

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease